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Background and Purpose: The morbidity and early mortality associated with stroke
is largely attributable to cerebral edema and elevated intracranial pressure (ICP).
Existing pharmacotherapies do not target the underlying pathophysiology and are often
ineffective in sustainably lowering ICP, whilst decompressive craniectomy (DC) surgery
is life-saving yet with surgical/peri-operative risk and increased morbidity in the elderly.
Accordingly, there is an urgent need for therapies that directly target the mechanisms of
edema genesis. Neurogenic inflammation, mediated by substance P (SP) binding to the
tachykinin NK1 receptor (NK1-r), is associated with blood-brain barrier (BBB) disruption,
cerebral edema and poor outcome post-stroke. NK1-r antagonist treatment ameliorates
BBB dysfunction and cerebral edema in rodent stroke models. However, treatment
has not been investigated in a large animal model, an important step toward clinical
translation. Consequently, the current study compared the efficacy of NK1-r antagonist
treatment to DC surgery in reducing ICP post-stroke in a clinically relevant ovine model.
Methods: Anesthetized female Merino sheep (65 ± 6 kg, 18–24 months) underwent
sham surgery (n = 4) or permanent middle cerebral artery occlusion (n = 22). Stroke
animals were randomized into one of 5 treatments: 1×NK1 bolus (4 h), 2×NK1 bolus
(4 h;9 h), 3×NK1 bolus (4 h;9 h;14 h), DC surgery (performed at 4 h) or saline vehicle.
ICP, blood pressure and blood gasses were monitored for 24 h post-stroke. At 24 h
post-stroke anesthetized animals underwent MRI followed by perfusion and brains
removed and processed for histological assessment.
Results: 2×NK1, 3×NK1 administration or DC surgery significantly (p < 0.05) reduced
ICP compared to vehicle. 1×NK1 was ineffective in sustainably lowering ICP. On MRI,
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midline shift and cerebral edema were more marked in vehicles compared to NK1-r
treatment groups.
Conclusion: Two or three boluses of NK1-r antagonist treatment reduced ICP
comparable to DC surgery, suggesting it may provide a novel alternative to invasive
surgery for the management of elevated ICP.
Keywords: intracranial pressure, cerebral edema, substance P, decompressive craniectomy, blood-brain
barrier, stroke
INTRODUCTION
Elevated intracranial pressure (ICP) arising as a result of
malignant cerebral edema is the leading cause of death in
the first week following stroke (Hacke et al., 1996). Despite
the devastating impact of elevated ICP on patient outcome,
clinical management remains sub-optimal. Pharmacological
interventions for ICP management are limited, and while osmotic
therapies (including mannitol and hypertonic saline) are used
in some centers (Zhang et al., 2018), there is no evidence
that these therapies are independently effective in improving
outcome. Furthermore, the efficacy of other pharmacotherapies
including corticosteroids and barbiturates remains ambiguous
for the treatment of post-stroke cerebral edema (Brogan and
Manno, 2015). In selected patients with malignant middle
cerebral artery (MCA) territory infarction, surgical intervention
with decompressive craniectomy (DC) may be required. This
procedure rapidly alleviates pressure by removing a large portion
of the skull and opening the dura overlying the brain, thereby
providing space for the edematous brain to swell freely until
cerebral edema resolves, typically beyond the first week following
stroke (Xiao-feng et al., 2005). However, although this procedure
reduces compression on cerebral structures and the risk of
life-threatening tonsillar herniation, it is also associated with
increased morbidity in those aged greater than 60 years, the
patient population in which stroke is most prevalent (Jüttler et al.,
2007; Das et al., 2019). It is clear that current pharmacological
and surgical interventions are inadequate as they target the
symptoms, rather than the underlying cause of cerebral edema
and concomitant rise in ICP (Bardutzky and Schwab, 2007;
Simard et al., 2007). An enhanced understanding of the
mechanisms that underlie the genesis of cerebral edema and
raised ICP is critical for the development of more targeted and
effective treatments.
Although factors associated with the pathogenesis of cerebral
edema are not completely understood, neurogenic inflammation
has been identified as a potential therapeutic target (Stumm et al.,
2001; Turner et al., 2006; Corrigan et al., 2016a). Neurogenic
inflammation is a neurally mediated process involving the release
of neuropeptides, including substance P (SP) and calcitonin
gene-related peptide, which initiate vasodilation, increased
microvascular permeability and edema (Hokfelt et al., 2000).
Although well established as a precipitant of edema development
within peripheral tissues such as the skin and lungs (Alves et al.,
1999), neurogenic inflammation remained largely unexplored
as a potential mechanism of cerebral edema development
(Lewis et al., 2013; Sorby-Adams et al., 2017). This was until
studies depleting neuropeptides or blocking the action of SP
at the tachykinin NK1 receptor (NK1-r), to which SP binds
preferentially, showed a ubiquitous role for this process in
the genesis of cerebral edema following stroke and traumatic
brain injury (TBI) (Vink et al., 2003; Nimmo et al., 2004;
Turner et al., 2006, 2011; Donkin et al., 2009; Turner and Vink,
2012, 2014; Corrigan et al., 2016a). Specifically, increased SP
immunoreactivity within the penumbral perivascular tissue is
associated with profound BBB disruption and cerebral edema
at 24 h post-stroke and poor functional outcomes up to 7 days
following middle cerebral artery occlusion (MCAO) in rats,
with NK1-r blockade ameliorating these effects (Turner et al.,
2011; Turner and Vink, 2012, 2014; Corrigan et al., 2016a).
Increased plasma SP levels have also been reported clinically
following severe acute ischemic stroke, elevated levels of which
were associated with increased mortality (Lorente et al., 2016).
Comparable alterations in SP levels have also been observed
in clinical TBI correlating with injury severity and mortality
(Lorente et al., 2015).
The cumulative evidence from these studies suggests an
important role for SP in the development of cerebral edema
and poor outcome following acute CNS injury. However, pre-
clinical stroke evaluation of the NK1-r antagonist has been
limited to small animal stroke models, with the most extensive
screening to date performed in small and large animal models
of TBI. Whilst rodent species are essential for establishing
basic biological processes, it is often difficult to obtain clinically
relevant outcome measures, thereby limiting clinical translation.
Given the extremely poor translation of stroke neuroprotection
from the laboratory to the clinic (Xu and Pan, 2013), evaluation
of promising therapies in a large, intermediate species is
essential. Species such as sheep are an ideal candidate for such
studies due to the ability to utilize clinically relevant outcome
measures in addition to similarities in neuroanatomical structure,
including gyrencephalic cerebral organization and significant
portion of white matter (Sorby-Adams et al., 2018). Of particular
relevance when investigating elevated ICP, however, is the
strong tentorium cerebelli of the sheep, separating supra- and
infratentorial compartments, bearing structural similarity to that
of the human (Dostovic et al., 2016). In the setting of clinical
malignant cerebral edema, this leads to compartmentalization
of pressure within the supratentorial space, tonsillar herniation,
and ultimately often fatal compression of the brain stem as the
brain attempts to alleviate dangerously elevated ICP. Indeed,
ovine stroke models replicate key clinical hallmarks following
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stroke including elevated ICP, cerebral edema, midline shift
and tonsillar herniation (Wells et al., 2012; Wells et al., 2015;
Sorby-Adams et al., 2018).
As such, the aim of the present study was to determine the
effect of inhibition of SP with an NK1-r antagonist, compared
to DC surgery, on ICP following permanent ischemic stroke
in an ovine model.
MATERIALS AND METHODS
Animals and Experimental Design
Female Merino sheep (n = 26) aged 18–24 months old (65± 6 kg)
were allocated to the study. Animals were randomized into either
sham surgery or permanent MCA occlusion (MCAO). Following
induction of stroke animals were then randomized into one of the
following groups: (1) saline vehicle treatment at 4 h post-stroke
(n = 6); (2) 1× bolus NK1 antagonist at 4 h post-stroke (n = 3); (3)
2× boluses of NK1 antagonist at 4 h and 9 h post-stroke (n = 3);
(4) 3× boluses of NK1 antagonist at 4, 9 and 14 h post-stroke
(n = 6); or (5) decompressive craniectomy (n = 5) at 4 h post-
stroke. Note that the dose for the NK1-r antagonist treatment
was the same across all the NK1-r treatment groups, the only
difference was the number of boluses that each group received,
either one (1×NK1), two (2×NK1), or three (3×NK1) boluses.
The NK1-r antagonist used in the study was a test compound
supplied by PresSuraNeuro prepared at a concentration of
1 mg/ml in warmed saline (37◦C) and administered at a dose of
1 ml/kg via an indwelling jugular venous catheter, as per previous
studies in our laboratory (Vink et al., 2017).
Anesthesia and Physiological Monitoring
Anesthesia was induced with intravenous thiopentone (1000 mg
in 20 mL, Jurox Pty Ltd., Australia) and maintained with
1.5% inhalational isoflurane (Veterinary Companies of Australia
Pty Ltd., Australia) in a mixture of oxygen and room air
(500:5000 ml/min), plus intravenous ketamine (Parnell Australia
Pty Ltd., Australia) infusion at 4 mg/kg/hr via a femoral venous
line. These two anesthetic agents were used in combination to
avoid the intrinsic neuroprotective properties of either above
certain doses, and to maintain a twilight general anesthesia
(Hudetz and Pagel, 2010; Schifilliti et al., 2010). With the animal
supine, an arterial catheter was placed in the right femoral artery
for continuous blood pressure monitoring and periodic arterial
blood gas sampling, and a venous catheter inserted for anesthetic
and fluid administration. The animal was then placed prone
in the sphinx position, a burr hole drilled in the right parietal
bone posterior to the coronal suture and approximately 20 mm
from the sagittal suture, dura perforated, and skull bolts secured.
A Codman microsensor ICP probe (Codman & Shurtleff Inc.,
MA, United States) was introduced into the bolt, calibrated
and inserted intraparenchymally to measure ICP within the
supratentorial compartment. Using LabChart Reader (v 8.1.1),
mean arterial blood pressure (MABP) and ICP were continuously
recorded through the 24 h monitoring period. Arterial blood
gas sampling was conducted prior to MCAO or sham surgery
and at hourly intervals throughout the monitoring period until
the completion of the experiment to maintain physiological
pO2, pCO2, and pH.
Surgical Approach to MCAO
We have previously described the surgical approach to proximal
MCAO in detail (Wells et al., 2012, 2015). Briefly, a 50 mm
vertical incision was made posterior to the right eye, terminating
at the zygomatic arch. The underlying muscle was retracted,
coronoid process removed, and the skull revealed. A small
craniotomy was performed at the junction of the parietal
and squamous temporal bones with a high-speed pneumatic
drill using a 5 mm cutting burr (Midas Rex, Medtronic,
MN, United States). All intra-dural work was carried out
with loupe magnification and a head mounted light source
(Surgical Acuity, WI, United States). A horse-shoe shaped
durotomy was performed with an inferiorly based flap allowing
for gentle upward retraction of the anterior temporal lobe
to achieve visualization of the proximal MCA. Animals then
either underwent sham surgery in which the proximal MCA
was dissected but not occluded, or permanent MCA in which
the proximal MCA was occluded via Malis bipolar diathermy
forceps (Valleylab Inc., CO, United States). The exposed brain
was irrigated with saline during surgery to prevent dehydration
of the cerebral cortex. After completion of sham or MCAO
surgery the dura was approximated and synthetic dura (Durepair,
Medtronic) interleaved under the existing dura (in the case of
dural retraction following incision) and closed watertight with
ethyl cyanoacrylate (Bostik, Australia). Once dural closure was
confirmed and no leakage of CSF observed, the craniotomy
site was reinforced with dental acrylic cement (Lang Dental,
IL, United States) that was manipulated into the edge of the
craniotomy and the wound closed in layers, maintaining the
shape of the cranial cavity and importantly, the homeostasis
of ICP dynamics. For animals allocated to the DC group,
at 4h following stroke the wound was opened, dental acrylic
removed, and the craniotomy site widened (3 cm × 6 cm)
to allow for decompression. A dural pouch was created using
Durepair to expand the intracranial cavity, after which the bone
was left off and the overlying skin sutured closed, simulating
clinical DC and expansile duraplasty. For all groups, the head
was then returned to a neutral position for monitoring under
general anesthesia.
Magnetic Resonance Imaging
At 24 h following stroke or sham surgery onset animals were
placed under general anesthesia (3% isoflurane) in a 1.5 Tesla
Siemens Sonata (Siemens AG, Munich, Germany) magnetic
resonance imaging (MRI) scanner. The scanning sequence
included time-of-flight magnetic resonance angiography (TOF
MRA; TR 26.0 ms, TE 3.69 ms, slice thickness 0.50 mm, slices
per slab 48), diffusion weighted imaging (DWI; TR 5600.0 ms, TE
80 ms, slice thickness 3.0 mm, slices per slab 25), fluid attenuated
inversion recovery (FLAIR; TR 5000.0 ms, TE 386 ms, slice
thickness 0.9 mm, slices per slab 96), T1 (TR 2300.0 ms, TE
2.58 ms, slice thickness 0.9 mm, slices per slab 96) and T2 (TR
3200 ms, TE 410 ms, slice thickness 0.9 mm, slices per slab 96)
weighted images.
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The degree of midline shift on MRI was used as a marker of
the amount of expansion of the infarcted hemisphere, indicative
of cerebral edema. Extent of shift from the midline was assessed
using axial T2-weighted scans and measured in mm from the
septum pellucidum at the level of the foramen of Monro (Horos
DICOM image viewer v3.1.1). To calculate cerebral edema,
coronal FLAIR images were analyzed using Horos (v3.1.1). After
optimal adjustment of brightness and contrast, edema volume
was determined from sequences using computer-aided manual
tracing of the hyperintense lesion by a blinded assessor. The areas
were then summed and multiplied by the slice thickness to give a
total volume in cm3.
To calculate infarct volume, segmentation tools in ITK-SNAP
(v 3.7) were used to perform semi-automated segmentation
of the MRI diffusion lesions using diffusion-weighted images
(Yushkevich et al., 2006). A combination of “three-dimensional
active contour segmentation” and subsequent manual post-
processing of the segmentation while adjusting image thresholds
was performed to maximize reproducibility whilst excluding
artifacts. The “three-dimensional active contour segmentation”
consisted of multiple steps: First, in the pre-segmentation phase,
independent component analysis automatically segmented parts
of the DWI image and these were manually identified as
foreground or background. To obtain an optimal distinction
between foreground and background, thresholds of the image
windows were adjusted. After thresholding, a “speed image” with
a separate foreground and background was created. Next, in the
active contour phase, seed regions were manually placed within
the region of interest (ROI). These seeds were then automatically
grown within the ROIs to form the temporary segmentation.
Subsequently, areas that were not automatically included in
the “active contour segmentation,” were manually included in
the follow-up infarct segmentation. The total volume of the
segmentation was exported and reported in cm3 for analysis.
Histological Examination
Following MRI, intravenous heparin (5000I.U./5 ml; Pfizer, NY,
United States) was administered and animals euthanized via
common carotid perfusion fixation with cold Tris–buffered
saline under Isoflurane anesthesia. The brains were subsequently
removed and sliced into 10 mm coronal slices using a custom-
made matrix. Sections were then immersion fixed in 10%
neutral-buffered formalin for a minimum of 14 days prior
to being processed, embedded in paraffin wax and sectioned
coronally at 5 micron intervals for histological examination
by hematoxylin and eosin (H&E), albumin (1:2000, Dako Pty
Ltd., A0001), SP (1:5000 citrate retrieval, Abcam Pty Ltd.,
ab14184), NKI-r (1:1000 citrate retrieval, Advanced Targeting
Systems Pty Ltd., AB-N-33AP) and caveolin-1 (cav-1; 1:1000
EDTA retrieval, Cell Signaling Technologies Pty Ltd., 3238)
immunohistochemistry.
Statistical Analysis
All data are expressed as mean ± SD. Physiological data (arterial
blood pressure, pH, pO2, pCO2) were analyzed using one-way
analysis of variance (ANOVA) followed by Tukey’s post hoc
tests (Prism v.8.0.1, Graphpad, CA, United States). Values were
averaged for each treatment group across all time points and
reported as a single value. Raw ICP and MABP data underwent
a logarithmic exponential transformation as previously described
and were expressed as geometric mean ± SD (Matthews et al.,
1990; Wells et al., 2015). ICP was analyzed by two-way ANOVA
and lesion volume, cerebral edema and midline shift data were
analyzed by one-way ANOVA, all followed by Tukey’s post hoc
tests. A p-value of < 0.05 was considered significant. Correlations
were performed between cerebral edema and midline shift and
ICP and cerebral edema to determine the relationship between
these variables.
RESULTS
Surgery, Mortality and Physiological
Parameters
All experimental procedures were carried out without
complication and there was no premature mortality or
unexpected events in any of the groups. Basic physiological
parameters are expressed in Table 1. For all groups, there was
no statistically significant difference in pO2, pCO2, or pH at
any of the time-points following stroke. However, there was
a statistically significant difference in MABP between sham,
1×NK1 (p = 0.02) DC (p = 0.02) and 3×NK1 (p = 0.006)
treatment groups.
Intracranial Pressure
Intracranial pressure remained physiologically stable across all
time points in sham animals (9 ± 3 mmHg). At both 4 and 9 h
post-stroke, there was no significant difference in ICP between
sham or any of the stroke groups. By 14 h following injury, ICP
in vehicle animals was significantly elevated (24 ± 11 mmHg)
compared to shams (10 ± 3 mmHg) (p = 0.019). However, no
difference in ICP was seen between vehicle or any of the treatment
groups at this time-point (Figure 1).
Intracranial pressure in vehicle animals continued to rise
and by 19 h post-stroke measured 32 ± 11 mmHg, which was
significantly elevated (p = 0.0002) compared to shams recording
an ICP of 13± 6 mmHg. By 19 h there was a significant reduction
in ICP seen in 2×NK1 (18 ± 4 mmHg; p = 0.013), 3×NK1
(17 ± 7 mmHg; p = 0.015), and DC (19 ± 11 mmHg; p = 0.042)
treated animals compared to vehicle. Conversely, there was no
reduction (p > 0.05) in ICP seen following 1×NK1 treatment









Sham 43 ± 8.41 113 ± 14.09 79 ± 8.78 7.48 ± 0.039
Vehicle 40 ± 6.09 127 ± 31.28 104 ± 10.17 7.46 ± 0.062
1×NK1 36 ± 2.55 138 ± 25.06 112 ± 10.18 7.51 ± 0.033
2×NK1 43 ± 6.56 149 ± 33.99 98 ± 5.81 7.45 ± 0.031
3×NK1 37 ± 2.34 135 ± 20.53 111 ± 15.66 7.52 ± 0.018
DC 42 ± 3.78 150 ± 17.22 108 ± 10.65 7.45 ± 0.082
Frontiers in Neuroscience | www.frontiersin.org 4 July 2019 | Volume 13 | Article 681
fnins-13-00681 July 4, 2019 Time: 16:10 # 5
Sorby-Adams et al. NK1-r Antagonist Reduces ICP
FIGURE 1 | 24 h ICP following MCAO. There was no significant difference in
sham ICP across any of the time points. At 14 h post-stoke ICP was elevated
in vehicle animals compared to sham (p < 0.05) and by 19 h post-stroke, ICP
was significantly elevated in vehicle (p < 0.001) and 1×NK1 (p < 0.01) treated
animals when compared to 2×NK1 (p < 0.05), 3×NK1 (p < 0.05) and DC
treatment groups (p < 0.05). By 24 h, ICP remained significantly elevated in
vehicle animals compared to sham (p < 0.0001), 2×NK1 (p < 0.01), 3×NK1
(p < 0.01) and DC (p < 0.05) treatment groups. ICP also remained elevated at
24 h post-stroke in 1×NK1 treatment groups compared to sham (p < 0.001)
and 2×NK1 (p < 0.05). Data presented as mean ± SD. ∗p < 0.05 compared
to sham; †p < 0.05 compared to vehicle.
(31 ± 9 mmHg) compared to vehicle, with ICP remaining
significantly elevated compared to sham (p = 0.002).
By 24 h post-stroke, ICP in vehicle animals had continued
to rise (39 ± 7 mmHg) and remained significantly elevated
compared to shams (12 ± 8 mmHg; p < 0.001), DC
(23 ± 12 mmHg; p = 0.013), 2×NK1 (20 ± 6 mmHg; p < 0.001),
and 3×NK1 (19 ± 7 mmHg; p < 0.005) treated animals. ICP
continued to rise in the 1×NK1 treatment group (35± 9 mmHg)
and remained significantly elevated compared to both shams
(p < 0.001) and 2×NK1 (p = 0.029) treatment groups. ICP in
2×NK1 and 3×NK1 treatment groups was comparable (p > 0.05)
to DC across all time points following stroke. No rebound
increases in ICP were observed following 2×NK1 or 3×NK1
treatment at any time-point post-stroke.
MRI
Magnetic resonance imaging was unremarkable in sham animals
(n = 4) with no evidence of cerebral edema, midline shift or
infarction (Figure 2A). All stroke animals showed evidence of
hyperintensity on T2-weighted and FLAIR images in the territory
MCA, indicative of the infarct core and surrounding vasogenic
edema (Figure 2). In addition, DC treated animals showed
evidence of transcalvarial herniation through the craniectomy
site (Figure 2D). No animals showed evidence of tonsillar
herniation or brain stem compression on MRI (data not shown).
Cerebral edema calculated on FLAIR MRI (Figure 3 and
Table 2) was reduced in DC (p = 0.012) and 1×NK1 treatment
groups (p = 0.042) when compared to vehicle (Figure 3A).
However, treatment with 2×NK1 (p = 0.001) and 3×NK1
FIGURE 2 | MRI findings 24 h post-MCAO. There was no evidence of
hyperintensity or tissue deformation seen in sham animals (A). Midline shift
was evident in all stroke animals as seen on axial T2-weighted images (B–D).
Cerebral edema as shown in coronal FLAIR MRI images was greater in vehicle
(B), DC (F) and 1×NK1 (C) groups compared with 2×NK1 (D) and 3×NK1
(E) groups. This was associated with a smaller diffusion lesion volume as
shown in DWI ADC images in the coronal plane. Note the transcalvarial
herniation through the craniotomy site in DC treated animals (F).
(p = 0.001) was associated with a more significant reduction
in cerebral edema volume compared to vehicle (Figure 3A).
Midline shift was evident in all stroke animals (Table 2) with no
statistical significance seen between groups (p = 0.2; Figure 3B).
Nevertheless, there was a moderate positive relationship between
the volume of cerebral edema and the degree of midline shift
(r = 0.46; Figure 3C). No significant differences (p = 0.17) were
observed in infarct volume across any of the treatment groups
following stroke, as measured on DWI MRI (Figure 3D).
Histological Analysis
H&E
There was no evidence of tissue injury or infarction in sham
tissue (Figure 4A). Following stroke (Figure 4B) there was
marked tissue pallor and loss of gray-white matter differentiation,
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FIGURE 3 | Cerebral edema and infarct volume findings at 24 h post-MCAO. Cerebral edema volume, as measured on FLAIR MRI (A), was decreased in 1×NK1
(p < 0.05), 2×NK1 (p < 0.001), 3×NK1 (p < 0.01), and DC (p < 0.05) treatment groups when compared to vehicle. There was no difference in midline shift in any of
the vehicle or treatment groups post-stroke (B). Despite this, there was a relative moderate positive correlation between cerebral edema and midline shift (C). There
was also a moderate positive correlation between cerebral edema and ICP measured at 24 h post-stroke (D). There was no significant difference in infarct volume
(E) as measured on DWI MRI between any treatment groups. ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 compared to vehicle.
indicative of infarction within the MCA territory of the
right hemisphere. 1×NK1 (Figure 4C) treatment tissue was
comparable to vehicles, however, there was an increased
preservation of tissue, in particular the sub-cortical white matter,
in the 2×NK1 (Figure 4D), 3×NK1 (Figure 4E) and DC
(Figure 4F) treated groups.
Albumin
There was minimal evidence of albumin extravasation
in sham tissue (Figure 4A). Following stroke, marked
albumin extravasation, indicative of BBB breakdown and
subsequent vasogenic cerebral edema formation, was observed
both macroscopically within the infarcted territory and
microscopically in the perivascular tissue of the infarct in
vehicles (Figure 4B), 1×NK1 (Figure 4C) and DC (Figure 4F),
when compared to shams (Figure 4A), 2×NK1 (Figure 4D) and
3×NK1 (Figure 4E) treatment groups.
SP
There was low to no observable immunoreactivity of SP in
sham tissue (Figure 5A). Furthermore, similarly low levels of SP
immunoreactivity were observed in the infarcted hemisphere of
vehicle and each of the treatment groups following stroke.
NK1-r
Low levels of perivascular NK1-r immunoreactivity were
observed in sham tissue (Figure 5B). Following stroke, an
increase in perivascular NK1-r immunoreactivity was observed
in vehicle and DC treated groups, which was not observed in any
of the NK1 treatment groups.
Cav-1
Little to no perivascular cav-1 immunoreactivity was observed
in sham tissue (Figure 5C). Following stroke, a marked increase
in perivascular cav-1 immunoreactivity was observed in vehicles
(E), 1×NK1 (F) and DC (L) tissue when compared to sham (D),
2×NK1 (J) and 3×NK1(K) tissue.
DISCUSSION
In this study we have demonstrated that administration of
two or three boluses of an NK1-r antagonist is effective
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86 19.48 1.8 33.9
87 36.45 3.5 24.5
60 20.96 3 25.9
66 31.14 2 34.4
57 27.61 3.5 20.1
59 23.32 3.4 56.5
Mean ± SD 25.56 ± 6.10 2.87 ± 0.71 32.55 ± 11.85
1×NK1
69 10.84 1.8 22.1
75 21.51 3.2 23
88 11.44 2.2 12.7
Mean ± SD 14.60 ± 6.0 2.40 ± 0.72 19.27 ± 5.70
2×NK1
70 4.230 0.8 8.3
72 3.520 0.5 17.2
91 11.789 2.6 34.7
Mean ± SD 6.51 ± 4.58 1.30 ± 1.14 20.07 ± 13.43
3×NK1
71 5.49 1.8 11.6
73 13.50 2.7 20.7
74 7.56 0.7 10.6
76 8.33 1.1 20.8
89 18.23 4.1 32.1
90 16.27 1.7 23.7
Mean ± SD 11.56 ± 5.17 2.02 ± 1.23 19.92 ± 8.0
DC
101 19.38 2.6 26.8
102 15.46 2.9 23.7
105 15.74 1 16.6
106 12.80 1.4 15.6
107 8.36 1.8 24
Mean ± SD 14.35 ± 4.08 1.94 ± 0.78 21.34 ± 4.95
in reducing ICP following stroke in a clinically relevant
ovine model. This reduction in ICP following treatment was
associated with improved BBB integrity, as shown by albumin
immunohistochemistry, and a trend toward reduction in the
volume of cerebral edema in the infarcted hemisphere. These
findings corroborate previous experimental (Vink et al., 2003;
Nimmo et al., 2004; Turner et al., 2006, 2011; Donkin et al.,
2009; Corrigan et al., 2012, 2016b; Turner and Vink, 2012,
2014) and clinical (Lorente et al., 2015, 2016) studies to further
support the role of SP in the pathogenesis of elevated ICP,
cerebral edema and increased permeability of the BBB following
acute CNS injury. Indeed, the reduction in ICP following
treatment observed in this study is consistent with findings
in an ovine model of TBI (Vink et al., 2017). Taken together,
we have now successfully demonstrated the efficacy of NK1-r
antagonist treatment for the reduction of cerebral edema and
its consequences in both rodent and sheep models of stroke
(Turner et al., 2006, 2011; Turner and Vink, 2012, 2014) and
TBI (Donkin et al., 2009; Corrigan et al., 2012, 2016b; Vink
et al., 2017). Taken together these findings clearly demonstrate
that SP release is a ubiquitous feature of acute CNS injury
and that blockade of this pathway is able to preserve BBB
integrity and halt the development of cerebral edema and
subsequent rise in ICP.
Despite the clear treatment effect of blocking the NK1-r
to reduce ICP in this study, we did not observe a significant
increase in perivascular SP immunoreactivity within the infarcted
territory in any of the treatment groups following stroke. This
is in keeping with our previous findings in a rodent model of
MCAO (Turner, 2007), where minimal SP immunoreactivity
was observed following permanent MCAO, yet profound
perivascular staining was identified following transient MCAO
with reperfusion. These observations are most likely due to the
fact that in the setting of permanent MCAO, the release and
peak in SP occurs acutely due to the severity of the ischemic
insult. As such, SP has likely been degraded by the time of tissue
harvest at 24 h post-stroke. In comparison, in previous rodent
transient MCAO studies, perivascular SP immunoreactivity
was observed primarily in the penumbral tissue. The relative
proportion of penumbra to ischemic core is likely to be much
less following permanent compared to transient MCAO due
to the extensive collateral failure with longer durations of
ischemia. Not surprisingly, this suggests that the magnitude and
timing of SP release in the neurogenic inflammatory response is
dependent upon the duration and severity of the ischemic insult
(Corrigan et al., 2016b). Indeed, following vascular occlusion,
temporary changes in transient receptor potential channels
of c-fibers as a result of alterations in temperature, pH and
ligand binding instigates release of SP (Hokfelt et al., 1975).
When there is no reperfusion, compromised cells undergo
ischemic necrosis quickly with associated acute changes in
cellular function, leading to a rapid return of receptor channel
potential and decrease in SP release. Comparatively, in the
setting of transient MCAO, compromised cells in the penumbra
experience long durations of electrical silence and alterations in
neuronal function, leading to sustained activation of c-fibers and
persistent SP release (Astrup et al., 1981; Turner, 2007; Hofmeijer
and Van Putten, 2012). Taken together, these findings may
provide an explanation as to why SP was not observed on
IHC in this study.
We did not observe any effect on infarct volume following
NK1-r antagonist treatment, irrespective of the number of
boluses administered. This is not surprising considering that
we used a permanent stroke model and given that the NK1-r
antagonist is targeting BBB disruption and not other pathways
in the ischemic injury cascade. Indeed, a transient stroke model
with reperfusion followed by delivery of an NK1-r antagonist may
yield different results on infarct volume. Nevertheless, we also
did not observe an effect on infarct volume at 24 hrs following
2 h MCAO thread occlusion in our rodent studies (Turner et al.,
2011). In these previous rat studies, however, we did demonstrate
that increased perivascular SP immunoreactivity was associated
with increased BBB permeability, profound cerebral edema
and persistent functional deficits (Turner et al., 2006, 2011;
Turner and Vink, 2012, 2014).
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FIGURE 4 | Hematoxylin and Eosin staining and albumin immunoreactivity in (A) sham, (B) vehicle, (C) 1×NK1, (D) 2×NK1, (E) 3×NK1, and (F) DC animals. H&E
staining shows evidence of pallor and reduced gray white matter differentiation, which is especially prominent in vehicles and 1×NK1 treated animals. Enhanced
albumin extravasation was seen macroscopically in vehicle, 1×NK1 and DC treated animals compared to sham, 2×NK1 and 3×NK1 treatment groups. This pattern
of albumin staining is consistent with the perivascular staining seen in microscopic images. Scale bar 50 µm, 40× magnification.
In this study we have identified that increased BBB
permeability was sustained to 24 h post-stroke in vehicle-
treated animals, as identified by the increased albumin
extravasation. Furthermore, the corresponding increase in
perivascular caveolin-1 immunoreactivity in the vehicle group
may provide an explanation for persistent changes barrier
permeability seen. Caveolae are invaginations of the plasma
membrane present in endothelial cells, including those that
comprise the BBB, with a key role in regulating transcytosis
of large molecules, including albumin, across the barrier
(Abbott et al., 2006). Cav-1 is an integral protein for caveolae
formation, with upregulation associated with enhanced albumin
extravasation and the development of vasogenic cerebral
edema (Nag et al., 2007). Furthermore, cav-1 is shown to be
upregulated following rodent cortical-cold injury and feline
TBI, despite maintenance of tight junction (TJ) integrity
(Povlishock et al., 1978; Nag et al., 2007), suggesting that
physical breakdown of the barrier through loss of TJ is not
necessary for the development of cerebral edema. The NK1-r
is located within caveolae, suggesting that its activation may
play a role in regulating transcytosis (Monastyrskaya et al.,
2005; Kubale et al., 2007). Indeed, this is consistent with
the observation of reduced barrier permeability following
NK1-r antagonist administration (Donkin et al., 2007; Turner
et al., 2011; Turner and Vink, 2012, 2014; Corrigan et al.,
2016a; Vink et al., 2017). It is proposed that SP release
following acute CNS injury leads to NK1-r activation, including
those located within the caveolae of endothelial cells. This
precipitates enhanced transcytosis of albumin across the barrier,
altering the osmotic gradient leading to the development of
vasogenic edema. Inhibition of transcytosis-mediated albumin
extravasation through administration of the NK1-r antagonist
attenuates unfavorable alterations in osmotic gradient across the
barrier, thus preventing the abnormal accumulation of water
in the parenchyma and subsequent development of edema
and rise in ICP.
As previously mentioned, in this study we were able
to reliability measure changes in ICP throughout the 24 h
monitoring period. Clinical studies investigating fluctuations in
ICP following malignant MCA stroke have recorded pressures
as high as 43 mmHg in patients that died, compared with
28 mmHg in survivors (Hacke et al., 1996). In the present
study pressures as high as 50 mmHg were recorded in vehicle
animals, however, two or three boluses of the NK1-r antagonist
were sufficient to sustainably reduce ICP to less than 30 mmHg.
Furthermore, 2×NK1 treated animals recorded pressures of less
than 20 mmHg throughout the 24 h monitoring period, with
the exception of one animal, and 3 boluses of the antagonist
was sufficient to maintain pressures below 25 mmHg, again with
the exception of one animal who recorded a maximum pressure
of 28 mmHg. One dose of the NK1-r antagonist, however, was
insufficient to produce a treatment effect with pressures averaging
35 mmHg. These findings suggest that multiple boluses of the
NK1-r antagonist is a potentially viable therapeutic strategy
to reduce elevated ICP following stroke, with the ability to
bring about a clinically meaningful and sustainable reduction
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FIGURE 5 | SP, NK1-r and caveolin-1 immunoreactivity. There was no identifiable increase in SP, NK1-r or cav-1 immunoreactivity in sham animals. Low levels of SP
immunoreactivity were seen perivascularly in vehicle, 1×NK1, 2×NK1, 3×NK1 and DC groups (A). This was concordant with an increase in NK1-r immunoreactivity,
which was most prominent in vehicle, 1×NK1 and DC animals (B). Cav-1 immunoreactivity was significantly enhanced in 1×NK1, 2×NK1 and DC treatment groups
when compared to vehicle and 1×NK1 (C). Scale bar: 50 µm, 40× magnification.
in pressure comparable to that observed in surviving patients
(Hacke et al., 1996).
Furthermore, the reduction in ICP we observed with repeated
NK1-r boluses was comparable to surgical decompression,
which is encouraging given the limitations of current
available pharmacotherapies used for ICP management,
often necessitating early DC. Indeed, DC performed before
clinical signs of herniation is shown to improve functional
outcomes however surgery performed after onset of clinical
deterioration may be too late to yield beneficial outcomes (Shah
et al., 2019). Furthermore, although DC is the most powerful
tool currently available to combat elevated ICP, the procedure is
highly invasive, benefits remain controversial and the long-term
implications of the procedure on ICP dynamics are not well
understood (Funchal et al., 2018; Lilja-Cyron et al., 2019; Shah
et al., 2019). A pooled analysis of the randomized control
trials DECIMAL, HAMLET, and DESTINY, compared early
DC with best available conventional medical management in
patients with evidence of MCA territory hypersensitivity and
a National Institute of Health Stroke Scale (NIHSS) > 15/20
(Jüttler et al., 2007; Vahedi et al., 2007a,b; Hofmeijer et al.,
2009; Geurts et al., 2013). These studies found that that DC
significantly reduced fatality rates and improved functional
outcome compared with conventional pharmacotherapy alone.
However, whilst some studies report reduced mortality and
improved survival, it is at the cost of a higher number of
individuals that are moderately severely disabled following
the procedure (Vahedi et al., 2007a; Kurland et al., 2015). This
becomes an issue of increasing concern given that DC is
associated with higher mortality rates in those aged greater than
60 years of age, the most prevalent stroke patient population
(Hofmeijer et al., 2009; Benjamin et al., 2018). The correlation
between age and functional outcome remains an extremely
important pre-treatment prognostic factor in deciding if patients
should undergo DC (Chen et al., 2007), further highlighting the
need for development of new therapies that can be administered
to a wider patient population in a safe and timely manner,
eliminating the need for surgical decompression and risk of
associated morbidity. In this study we have demonstrated
that repeated dosing of NK1-r antagonist treatment was able
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to reduce ICP comparable to DC surgery, thus providing
an alternate treatment strategy, circumventing the need for
invasive surgery.
Limitations
Although we have established that the NK1-r antagonist is
an effective strategy to lower ICP and we have previously
determined that the ovine model is viable candidate for the
screening of promising novel therapeutics, we must acknowledge
the limitations of the study.
Due to the invasive nature of the surgery and significant
deficits that ensued following permanent MCAO, animals were
required to be maintained under anesthesia for the duration of
the experiment. We recognize that human patients are rarely
under the influence of anesthesia on stroke onset, and that
the use of anesthetic agents may affect outcome measures.
Despite this, the agents used for induction and maintenance
were chosen to reduce any potential neuroprotective or damaging
effects, as previously described in detail (Wells et al., 2015).
Indeed, as ketamine is known for its neuroprotective properties,
and inhalation isoflurane for its sub-neuroprotection and
association with reduced blood pressure, the combination was
used to bring about a countering effect. The synergistic use
of these agents permitted adequate anesthesia with controlled
MABP whilst preventing inadvertent neuroprotection as a
confounding factor, an important consideration when modeling
acute ischemic stroke. It must be acknowledged, however,
that we did observe significant differences in MABP across
several of the groups. Nevertheless, these alterations in MABP
did not follow the same pattern as the alterations in ICP
so it is therefore unlikely that they significantly contributed
to the observed treatment effects. The differences in MABP
observed between groups most likely reflects both the within
group and between group heterogeneity in the amount of
isoflurane required to maintain twilight anesthesia during
surgery whilst balancing with ketamine to maintain adequate
blood pressure.
Furthermore, only female animals were used in the present
study due to the inherent need for catheterization of animals
during long-duration anesthesia. Females were selected
preferentially over males upon veterinary advice given the
difficulty in catheterizing the highly convoluted male urethra.
Though we were able to establish a significant increase in
ICP following ovine stroke, MRI findings were not strongly
correlated with ICP. Although the relationship between ICP and
cerebral edema well established and promising in this study,
we acknowledge that the small sample sizes in this study may
have led to a low statistical power. Furthermore, it must be
noted that this is frequently seen in clinical stroke cases, where
MRI and computed tomography (CT) findings are not always
a good predictor of ICP. Due to facility access, MRI was not
possible in the entire cohort, leading to uneven group sizes.
Despite a larger cohort available for ICP in both treatment and
vehicle groups, only animals with matching ICP/MRI data were
included, leading to variations in group sizes. Furthermore, the
reliable measurement of cerebral edema on MRI at a single
time-point is somewhat contentious, as the hyperintensity of
vasogenic edema is difficult to distinguish from the lesion
itself. The measurement of the entire FLAIR lesion volume
therefore includes areas of infarction as well as edema, and
is thus an indirect measure of edema volume. A more robust
approach to measuring edema evolution would be to perform
sequential MRI’s and evaluate the change in diffusion lesion
volume between 2 times points following reperfusion, which
was not possible in this study due to cost. It should also be
acknowledged that whilst MRI findings did not correlate with
ICP, we were able to observe MRI features similar to that
seen clinically, including transcalvarial herniation in DC treated
animals and reduced midline shift. Finally, testing of multiple
NK1-r antagonists was not feasible in this study given the time
and cost involved in conducting sheep experiments. However, in
our rodent studies of TBI we have previously tested 2 different
NK1-r antagonists and recorded comparable results (Donkin,
2006) which provided the basis for the use of the agent in
the present study.
For future studies we will work alongside the animal ethics
committee of the South Australian Health and Medical Research
Institute (SAHMRI) to develop a survival model of transient
MCAO which obviates the need for long duration anesthesia,
allowing for the study of conscious animals following induction
of stroke and assessment of long-term functional changes.
CONCLUSION
Multiple boluses of an NK1-r antagonist is effective in lowering
ICP following ovine stroke, producing a reduction in ICP
that is comparable to decompressive surgery. We propose that
the mechanism by which the NK1-r antagonist is exerting its
effect is largely via caveolae mediated albumin transcytosis.
Administration of the NK1-r is thus preventing abnormal
albumin extravasation from the vasculature to the brain
parenchyma and ameliorating the subsequent development of
vasogenic edema and rise in ICP. These findings suggest that
NK1-r antagonist treatment may represent a novel intervention
for the management of elevated ICP following stroke.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or the supplementary files.
ETHICS STATEMENT
All experimental procedures were approved by the Animal Ethics
Committees of the University of Adelaide (M-2011-240) and
the South Australian Health and Medical Research Institute
(SAHMRI; SAM104/11) and conducted according to guidelines
established for the use of animals in experimental research as
outlined by the Australian National Health and Medical Research
Council code of practice for the care and use of animals for
scientific purposes (8th edition, 2013).
Frontiers in Neuroscience | www.frontiersin.org 10 July 2019 | Volume 13 | Article 681
fnins-13-00681 July 4, 2019 Time: 16:10 # 11
Sorby-Adams et al. NK1-r Antagonist Reduces ICP
AUTHOR CONTRIBUTIONS
AW, RV, RT, and AL conceived and designed the experiments.
AW, RT, and AL carried out the experiments. AS-A, NY, JH, and
RT analyzed the data. AS-A, RT, and AL wrote the manuscript.
FUNDING
This work was supported by the National Health and Medical
Research Council (NHMRC; Project grant GNT1082556) and
by the Neurosurgical Research Foundation (Adelaide, SA,
Australia). RT was supported by the NHMRC Post-Doctoral
Training Fellowship. AW was supported by the NHMRC Post-
Graduate Fellowship.
ACKNOWLEDGMENTS
We would like to thank Sunthara Rajan Perumal for the
acquisition of the MRI and Shenyi Peng, Tony Nguyen, and
Martina Kontos for their contribution to the MRI analysis.
We would also like to acknowledge the facilities and scientific
and technical assistance of the National Imaging Facility, a
National Collaborative Research Infrastructure Strategy (NCRIS)
capability, at LARIF and SAHMRI.
REFERENCES
Abbott, N. J., Ronnback, L., and Hansson, E. (2006). Astrocyte-endothelial
interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53.
doi: 10.1038/nrn1824
Alves, R. V., Campos, M. M., Santos, A. R., and Calixto, J. B. (1999). Receptor
subtypes involved in tachykinin-mediated edema formation. Peptides 20,
921–927. doi: 10.1016/s0196-9781(99)00082-0
Astrup, J., Siesjo, B. K., and Symon, L. (1981). Thresholds in cerebral ischemia - the
ischemic penumbra. Stroke 12, 723–725. doi: 10.1161/01.str.12.6.723
Bardutzky, J., and Schwab, S. (2007). Antiedema therapy in ischemic stroke. Stroke
38, 3084–3094. doi: 10.1161/strokeaha.107.490193
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R.,
and Cheng, S. (2018). Heart disease and stroke statistics-2018 update: a report
From the American heart association. Circulation 137, e67-e492.
Brogan, M., and Manno, E. (2015). Treatment of malignant brain edema
and increased intracranial pressure after stroke. Cur. Treat. Options Neurol.
17, 1–11.
Chen, C.-C., Cho, D.-Y., and Tsai, S.-C. (2007). Outcome of and prognostic
factors for decompressive hemicraniectomy in malignant middle cerebral artery
infarction. J. Clin. Neurosci. 14, 317–321. doi: 10.1016/j.jocn.2005.05.024
Corrigan, F., Leonard, A., Ghabriel, M., Van Den Heuvel, C., and Vink, R. (2012).
A substance P antagonist improves outcome in female sprague dawley rats
following diffuse traumatic brain injury. CNS Neurosci. Ther. 18, 513–515.
doi: 10.1111/j.1755-5949.2012.00332.x
Corrigan, F., Mander, K. A., Leonard, A. V., and Vink, R. (2016a). Neurogenic
inflammation after traumatic brain injury and its potentiation of classical
inflammation. J. Neuroinflammation 13:264.
Corrigan, F., Vink, R., and Turner, R. J. (2016b). Inflammation in acute CNS
injury: a focus on the role of substance P. Br. J. Pharmacol. 173, 703–715.
doi: 10.1111/bph.13155
Das, S., Mitchell, P., Ross, N., and Whitfield, P. C. (2019). Decompressive
hemicraniectomy in the treatment of malignant middle cerebral artery
infarction: a meta-analysis. World Neurosurgery 123, 8–16. doi: 10.1016/j.wneu.
2018.11.176
Donkin, J. D. (2006). The effects of the neuropeptide substance P on outcome
following experimental traumatic brain injury in rats. Adelaide: University of
Adelaide.
Donkin, J. J., Nimmo, A. J., Cernak, I., Blumbergs, P. C., and Vink, R. (2009).
Substance P is associated with the development of brain edema and functional
deficits after traumatic brain injury. J. Cereb. Blood Flow Metab. 29, 1388–1398.
doi: 10.1038/jcbfm.2009.63
Donkin, J. J., Turner, R. J., Hassan, I., and Vink, R. (2007). Substance P in traumatic
brain injury. Prog. Brain Res. 161, 97–109.
Dostovic, Z., Dostovic, E., Smajlovic, D., Ibrahimagic, O. C., and Avdic, L. (2016).
Brain edema after ischaemic stroke. Med. Arch. 70, 339–341.
Funchal, B. F., Alves, M. M., Suriano, I. C., Chaddad-Neto, F. E.,
Ferraz, M., and Silva, G. S. (2018). Intracranial pressure following
decompressive hemicraniectomy for malignant cerebral infarction:
clinical and treatment correlations. Arq Neuropsiquiatr. 76, 812–815.
doi: 10.1590/0004-282X20180132
Geurts, M., Van Der Worp, H. B., Kappelle, L. J., Amelink, G. J., Algra, A.,
and Hofmeijer, J. (2013). Surgical decompression for space-occupying cerebral
infarction: outcomes at 3 years in the randomized HAMLET trial. Stroke 44,
2506–2508. doi: 10.1161/STROKEAHA.113.002014
Hacke, W., Schwab, S., Horn, M., Spranger, M., De Georgia, M., and Von Kummer,
R. (1996). ‘Malignant’ middle cerebral artery territory infarction: clinical course
and prognostic signs. Arch. Neurol. 53, 309–315.
Hofmeijer, J., Kappelle, L. J., Algra, A., Amelink, G. J., Van Gijn, J., and Van
Der Worp, H. B. (2009). Surgical decompression for space-occupying cerebral
infarction (the hemicraniectomy after middle cerebral artery infarction with
life-threatening edema trial [HAMLET]): a multicentre, open, randomised trial.
Lancet. Neurol. 8, 326–333. doi: 10.1016/S1474-4422(09)70047-X
Hofmeijer, J., and Van Putten, M. J. (2012). Ischemic cerebral damage: an appraisal
of synaptic failure. Stroke 43, 607–615. doi: 10.1161/STROKEAHA.111.632943
Hokfelt, T., Broberger, C., Xu, Z. Q., Sergeyev, V., Ubink, R., and Diez, M.
(2000). Neuropeptides–an overview. Neuropharmacology 39, 1337–1356.
doi: 10.1016/s0028-3908(00)00010-1
Hokfelt, T., Kellerth, J. O., Nilsson, G., and Pernow, B. (1975). Substance P:
localisation in the central nervous system and in some primary sensory
neurones. Science 190, 889–890. doi: 10.1126/science.242075
Hudetz, J. A., and Pagel, P. S. (2010). Neuroprotection by ketamine: a review of the
experimental and clinical evidence. J. Cardiothorac. Vasc. Anesth. 24, 131–142.
doi: 10.1053/j.jvca.2009.05.008
Jüttler, E., Schwab, S., Schmiedek, P., Unterberg, A., Hennerici, M., Woitzik, J., et al.
(2007). Decompressive surgery for the treatment of malignant infarction of the
middle cerebral artery (DESTINY): a randomized, controlled trial. Stroke 38,
2518–2525. doi: 10.1161/strokeaha.107.485649
Kubale, V., Abramovic, Z., Pogacnik, A., Heding, A., Sentjurc, M., and Vrecl, M.
(2007). Evidence for a role of caveolin-1 in neurokinin-1 receptor plasma-
membrane localization, efficient signaling, and interaction with beta-arrestin
2. Cell Tissue Res. 330, 231–245. doi: 10.1007/s00441-007-0462-y
Kurland, D. B., Khaladj-Ghom, A., Stokum, J. A., Carusillo, B., Karimy,
J. K., Gerzanich, V., et al. (2015). Complications associated with
decompressive craniectomy: a systematic review. Neurocrit. care 23, 292–304.
doi: 10.1007/s12028-015-0144-7
Lewis, K. M., Turner, R. J., and Vink, R. (2013). Blocking neurogenic inflammation
for the treatment of acute disorders of the central nervous system. Int. J. Inflam.
2013:578480.
Lilja-Cyron, A., Andresen, M., Kelsen, J., Andreasen, T. H., Fugleholm, K.,
and Juhler, M. (2019). Long-term effect of decompressive craniectomy
on intracranial pressure and possible implications for intracranial fluid
movements. Neurosurgery doi: 10.1093/neuros/nyz049 [Epub ahead of
print].
Lorente, L., Martín, M. M., Almeida, T., Hernández, M., Ramos, L., Argueso,
M., et al. (2015). Serum substance p levels are associated with severity and
mortality in patients with severe traumatic brain injury. Crit. Care 19:192.
doi: 10.1186/s13054-015-0911-z
Frontiers in Neuroscience | www.frontiersin.org 11 July 2019 | Volume 13 | Article 681
fnins-13-00681 July 4, 2019 Time: 16:10 # 12
Sorby-Adams et al. NK1-r Antagonist Reduces ICP
Lorente, L., Martín, M. M., Almeida, T., Pérez-Cejas, A., Ramos, L., Argueso, M.,
et al. (2016). Serum Levels of Substance P and Mortality in Patients with a Severe
Acute Ischemic Stroke. Int.J. Mol. Sci. 17:991. doi: 10.3390/ijms17060991
Matthews, J. N., Altman, D. G., Campbell, M. J., and Royston, P. (1990).
Analysis of serial measurements in medical research. BMJ 300, 230–235.
doi: 10.1136/bmj.300.6719.230
Monastyrskaya, K., Hostettler, A., Buergi, S., and Draeger, A. (2005). The
NK1 receptor localizes to the plasma membrane microdomains, and its
activation is dependent on lipid raft integrity. J. Biol. Chem. 280, 7135–7146.
doi: 10.1074/jbc.m405806200
Nag, S., Venugopalan, R., and Stewart, D. J. (2007). Increased caveolin-1 expression
precedes decreased expression of occludin and claudin-5 during blood-brain
barrier breakdown. Acta Neuropathol. 114, 459–469. doi: 10.1007/s00401-007-
0274-x
Nimmo, A. J., Cernak, I., Heath, D. L., Hu, X., Bennett, C. J., and Vink, R.
(2004). Neurogenic inflammation is associated with development of edema and
functional deficits following traumatic brain injury in rats. Neuropeptides 38,
40–47. doi: 10.1016/j.npep.2003.12.003
Povlishock, J. T., Becker, D. P., Sullivan, H. G., and Miller, J. D. (1978). Vascular
permeability alterations to horseradish peroxidase in experimental brain injury.
Brain Res. 153, 223–239. doi: 10.1016/0006-8993(78)90404-3
Schifilliti, D., Grasso, G., Conti, A., and Fodale, V. (2010). Anaesthetic-related
neuroprotection intravenous or inhalational agents? CNS Drugs 24, 893–907.
doi: 10.2165/11584760-000000000-00000
Shah, A., Almenawer, S., and Hawryluk, G. (2019). Timing of decompressive
craniectomy for ischemic stroke and traumatic brain injury: a review. Front.
Neurol. 10:11. doi: 10.3389/fneur.2019.00011
Simard, J. M., Kent, T. A., Chen, M., Tarasov, K. V., and Gerzanich, V. (2007).
Brain oedema in focal ischaemia: molecular pathophysiology and theoretical
implications. Lancet. Neurol. 6, 258–268. doi: 10.1016/s1474-4422(07)70055-8
Sorby-Adams, A. J., Marcoionni, A. M., Dempsey, E. R., Woenig, J. A., and
Turner, R. J. (2017). The role of neurogenic inflammation in blood-brain barrier
disruption and development of cerebral oedema following acute central nervous
system (cns) injury. Int. J. Mol. Sci. 18:E1788.
Sorby-Adams, A. J., Vink, R., and Turner, R. J. (2018). Large animal models of
stroke and traumatic brain injury as translational tools. Am. J. physiol. Regul.
Integr. comp. physiol. 315, R165–R190. doi: 10.1152/ajpregu.00163.2017
Stumm, R., Culmsee, C., Schafer, M. K., Krieglstein, J., and Weihe, E. (2001).
Adaptive plasticity in tachykinin and tachykinin receptor expression after
focal cerebral ischemia is differentially linked to gabaergic and glutamatergic
cerebrocortical circuits and cerebrovenular endothelium. J. Neurosci. 21, 798–
811. doi: 10.1523/jneurosci.21-03-00798.2001
Turner, R. E. J. (2007). Characterising the role of substance P in acute ischaemic
stroke. Thesis. University of Adelaide. Adelaide.
Turner, R. J., Blumbergs, P. C., Sims, N. R., Helps, S. C., Rodgers, K. M., and
Vink, R. (2006). Increased substance P immunoreactivity and edema formation
following reversible ischemic stroke. Acta Neurochir Suppl. 96, 263–266.
doi: 10.1007/3-211-30714-1_56
Turner, R. J., Helps, S. C., Thornton, E., and Vink, R. (2011). A substance P
antagonist improves outcome when administered 4 h after onset of ischemic
stroke. Brain Res. 1393, 84–90. doi: 10.1016/j.brainres.2011.03.066
Turner, R. J., and Vink, R. (2012). Combined tissue plasminogen activator and
an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion
injury following acute ischemic stroke in rats. Neuroscience 220, 1–10.
doi: 10.1016/j.neuroscience.2012.06.047
Turner, R. J., and Vink, R. (2014). NK1 tachykinin receptor treatment is superior
to capsaicin pre-treatment in improving functional outcome following acute
ischemic stroke. Neuropeptides 48, 267–272. doi: 10.1016/j.npep.2014.07.002
Vahedi, K., Hofmeijer, J., Juettler, E., Vicaut, E., George, B., Algra, A., et al. (2007a).
Early decompressive surgery in malignant infarction of the middle cerebral
artery: a pooled analysis of three randomised controlled trials. Lancet. Neurol.
6, 215–222. doi: 10.1016/s1474-4422(07)70036-4
Vahedi, K., Vicaut, E., Mateo, J., Kurtz, A., Orabi, M., Guichard, J.-P., et al.
(2007b). Sequential-design, multicenter, randomized, controlled trial of early
decompressive craniectomy in malignant middle cerebral artery infarction
(DECIMAL Trial). Stroke 38, 2506–2517. doi: 10.1161/strokeaha.107.485235
Vink, R., Gabrielian, L., and Thornton, E. (2017). The Role of Substance P in
Secondary Pathophysiology after Traumatic Brain Injury. Front. Neurol. 8:304.
doi: 10.3389/fneur.2017.00304
Vink, R., Young, A., Bennett, C. J., Hu, X., Connor, C. O., Cernak, I., et al. (2003).
Neuropeptide release influences brain edema formation after diffuse traumatic
brain injury. Acta Neurochir. Suppl. 86, 257–260. doi: 10.1007/978-3-7091-
0651-8_55
Wells, A. J., Vink, R., Blumbergs, P. C., Brophy, B. P., Helps, S. C., Knox, S. J.,
et al. (2012). A surgical model of permanent and transient middle cerebral artery
stroke in the sheep. PLoS One 7:e42157. doi: 10.1371/journal.pone.0042157
Wells, A. J., Vink, R., Helps, S., Knox, S. J., Blumbergs, P. C., and Turner, R. J.
(2015). Elevated intracranial pressure and cerebral edema following permanent
mca occlusion in an ovine model. PLoS One 10:e0130512. doi: 10.1371/journal.
pone.0130512
Xiao-feng, Y., Yu, Y., Wei-Wei, H., Gu, L., Jin-Fang, X., Xue-Qun, Z., et al. (2005).
Is decompressive craniectomy for malignant middle cerebral artery infarction
of any worth? J. Zhejiang Univ. Sci. B 6, 644–649. doi: 10.1631/jzus.2005.b0644
Xu, S. Y., and Pan, S. Y. (2013). The failure of animal models of neuroprotection in
acute ischemic stroke to translate to clinical efficacy. Med. sci. Monit. Basic Res.
19, 37–45.
Yushkevich, P. A., Piven, J., Hazlett, H. C., Smith, R. G., Ho, S., Gee, J. C., et al.
(2006). User-guided 3D active contour segmentation of anatomical structures:
significantly improved efficiency and reliability. Neuroimage 31, 1116–1128.
doi: 10.1016/j.neuroimage.2006.01.015
Zhang, W., Neal, J., Lin, L., Dai, F., Hersey, D. P., Mcdonagh, D. L., et al.
(2018). Mannitol in critical care and surgery over 50+ years: a systematic
review of randomized controlled trials and complications with meta-analysis.
J. Neurosurg. Anesthesiol. 31, 273–284. doi: 10.1097/ANA.0000000000000520
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Sorby-Adams, Leonard, Hoving, Yassi, Vink, Wells and Turner.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 12 July 2019 | Volume 13 | Article 681
